OXIDANT INJURY TO THE PULMONARY endothelium is an important contributor to the pathogenesis of acute lung injury (ALI) and the acute respiratory distress syndrome (52) . Increasing the antioxidant capacity of the pulmonary endothelium could potentially ameliorate oxidant-induced ALI (11, 26, 45) . In some clinical situations, such as cardiopulmonary bypass, aortic surgery, or lung transplantation, an endothelial oxidant insult predictably occurs, allowing the potential for a pretreatment to increase endogenous pulmonary endothelial antioxidant capacity (19, 30) . We and others (35, 37, 40, 56) have previously shown that increased pulmonary endothelial cGMP activated the serine/threonine kinase protein kinase G I (PKG I ) and blocked oxidant-induced pulmonary endothelial barrier dysfunction and attenuated pulmonary ischemia-reperfusion injury. Similar antioxidant effects of PKG I activation have been observed in other cell types, although the mechanism was not determined (16, 39) . We have recently shown that activation of PKG I increased catalase and glutathione peroxidase 1 (GPx-1) expression and activity and attenuated oxidant-induced injury in the pulmonary endothelium, suggesting an underlying mechanism behind the antioxidant effects of cGMP signaling (46) . The PKG I -mediated increase in catalase and GPx-1 protein expression was posttranscriptional. Both catalase and GPx-1 have been reported to be regulated in a posttranscriptional fashion by the c-Abl tyrosine kinase (8 -10) . c-Abl is activated by oxidative stress, which causes translocation of activated c-Abl from the cytoplasm to the mitochondria and nucleus (27, 47, 48, 50) . Activated c-Abl was shown to be proapoptotic (48) and to phosphorylate catalase tyrosine residues Y231 and Y386, resulting in catalase ubiquitination and degradation (10) . c-Abl also interacts with cell-adhesion proteins and the actin cytoskeleton, with variable effects on endothelial barrier function (9, 18, 55, 59 ). Inhibition of c-Abl with the tyrosine kinase inhibitor imatinib has been shown to be protective in a number of models of oxidant-induced injury (2, 22, 28) , but the specific mechanism has not been defined.
We hypothesized that the effect of PKG I activation on pulmonary microvascular endothelial antioxidant defenses was mediated by an inhibitory effect of PKG I on the c-Abl tyrosine kinase, leading to increases in catalase and GPx-1 and attenuation of endothelial oxidant injury. We further hypothesized that this effect of PKG I activation would be mimicked by administration of imatinib. We now report that activated PKG I inhibits c-Abl activity and downregulates c-Abl expression. Furthermore, the c-Abl inhibitor imatinib increases protein levels of catalase and GPx-1 in the pulmonary endothelium and attenuates oxidant-induced cytotoxicity and pulmonary microvascular endothelial barrier dysfunction.
MATERIALS AND METHODS
Antibodies and reagents. Anti-catalase and anti-pVASP(Ser239) antibodies were from CalBiochem (San Diego, CA). Anti-glutathione peroxidase-1 (Gpx-1) antibodies were obtained from Abcam. Total p73 and total c-Abl antibodies were from Santa Cruz Biotechnology (Dallas, TX). All other antibodies and cell lysis buffer concentrate were from Cell Signaling Technology (Beverly, MA). Secondary antibodies and all Western blotting reagents were from Bio-Rad (Hercules, CA). DMEM, Brinster's BMOC-3 media, FBS, and Trizol reagent were from Invitrogen (Carlsbad, CA). Imatinib was obtained from Cayman Biochemical and dissolved in serum-free DMEM. Hydrogen peroxide (H 2O2), BSA, rat atrial natriuretic peptide (ANP), and protease inhibitor cocktail were obtained from Sigma (St. Louis, MO). ANP was dissolved in sterile 0.9% NaCl. Endothelial cell growth supplement (ECGS) was from Millipore (02-102) (Billerica, MA).
Animals. All protocols in this study were approved by the Animal Care and Use Committee of the Johns Hopkins Medical Institutions. Male wild-type C57Bl/6 mice were obtained at 6 -8 wk from Jackson Laboratories (Bar Harbor, ME). PKG knockout mice have been previously described (38) . Mice were maintained by the Division of Comparative Medicine of Johns Hopkins University and were provided food and water ad libitum.
Mouse lung microvascular endothelial cell isolation and culture. Mouse lung microvascular endothelial cells (MLMVEC) were isolated and purified as previously described (46) . Briefly, mice were killed by cervical dislocation, a thoracotomy was performed, and the lungs were removed. Large airways were excluded, and the periphery of the lung was isolated. The lung was rinsed with DMEM (Invitrogen), minced, and digested in 1 ml collagenase (1 mg/ml; Sigma) at 37°C for 20 min. The digest was filtered through sterile mesh and centrifuged (400 g for 7 min). The pellet was resuspended in DMEM supplemented with 20% FBS, 150 g/ml ECGS, 100 g/ml penicillin/streptomycin, and 0.25 g/ml amphotericin B and placed in a 0.1% gelatin-coated T-25 flask. After reaching confluence, the cells were stained overnight with acetylated LDL/Alexa Fluor 488 conjugate (Molecular Probes/Invitrogen L23380) and sorted into a purified endothelial population using a FACS ARIA (Becton Dickinson, Franklin Lakes, NJ). Endothelial phenotype was confirmed by observing for typical cobblestone morphology and immunostaining for platelet endothelial cell adhesion molecule and von Willebrand factor. All experiments were performed with cells between passages 2 and 10.
Cell death assessment. Cell death was determined after exposure to H 2O2 by fluorescence microscopy and evaluation for apoptotic nuclear morphology as previously described (46) . Briefly, confluent monolayers of MLMVEC were treated with imatinib (10 and 20 M) or diluent for 2 h and then serum starved for an additional 2 h in the presence of imatinib or diluent for a total of 4 h of imatinib treatment. The cells were then incubated with H2O2 for 1 h followed by a change to complete media with imatinib or diluent. After 18 h, cells were stained with Hoechst and propidium iodide and examined with an Olympus IX 51 inverted fluorescence microscope for condensed and fragmented nuclear morphology consistent with apoptosis. Cells were counted in a blinded fashion with the outcome expressed as apoptic cells as a percentage of total cells. H2O2 electrode. Real-time H2O2 concentrations were measured with a H2O2 electrode system (Apollo 4000 Free Radical Analyzer; World Precision Instruments, Sarasota, FL) (46) . The ISO-HPO-2 electrode was mounted in a multiport water-jacketed sample chamber (NOCHM-4 Four-Port Closed Chamber; World Precision Instruments). MLMVEC from one well of a six-well plate were treated with imatinib (10 and 20 M) for 4 h, then washed twice with PBS, collected with trypsin, centrifuged, and resuspended in 2 ml of serum-free DMEM. The cell suspension was placed into the sample chamber, which was warmed to 37°C and continuously stirred with a magnetic stir bar. At intervals, H2O2 was added to achieve a specified predicted concentration in the cell suspension while continuously monitoring temperature and H2O2-induced current. The H2O2 signal was allowed to completely decay before the next concentration of H2O2 was added. The data were saved on a personal computer.
Gel electrophoresis and immunoblot analysis. Confluent monolayers of MLMVEC were harvested, and cell lysates were prepared as described previously (35, 46) .
Small interfering RNA. c-Abl and control small interfering (si)RNAs were obtained from Santa Cruz Biotechnology (sc-29844 and sc-37007). Transfection of siRNA was accomplished according to the manufacturer's protocol using siRNA transfection Reagent (sc-29528; Santa Cruz Biotechnology) and the siRNA Reagent System (sc-45064; Santa Cruz Biotechnology). Efficacy of knockdown was assessed via Western blotting.
Quantitative real-time RT-PCR. MLMVEC were rinsed once with ice-cold PBS, treated with TRIsol reagent (Invitrogen), sonicated, and purified using the RNeasy Mini Kit (Qiagen, Valencia, CA). RNA yield was calculated using spectrophotometry (NanoDrop, Wilmington, DE), and purity was assessed by A260/A280 ratio. Gene-specific primers were designed from mouse catalase mRNA (Accession No. NM_009804), Gpx1 mRNA (NM_008160), and GAPDH mRNA (NM_008084). The primers used for catalase were 5=-TATTGC-CGTTCGATTCTCCACAGT-3= and 5=-TTTCCCACAAGATC-CCAGTTACCA-3=. The Gpx-1 primers were 5=-TGCAATCAGTTCG-GACACCAG-3= and 5=-CATTCACTTCGCACTTCTCAAACA-3=. The primers for GAPDH were 5=-CTCATGACCACAGTCCATGC-3=, and 3=-ACATTGGGGTTAGGAACACG-5=.
RNA (0.5 g) from each sample was converted to cDNA (after genomic DNA wipeout) using QuantiTect Reverse Transcription kit (Qiagen). Quantitative real-time RT-PCR reactions were performed with QuantiTect SYBR Green PCR Master Mix (Qiagen) using 1 l of cDNA as the template in each 25-l reaction mixture. PCR assays were performed with a Chrom4 thermal cycler system (MJ Research, Waltham, MA). Cycling conditions were as follows: initial enzyme inactivation at 95°C for 15 min, followed by 40 cycles at 95°C for 20 s, 57°C for 30 s, and 72°C for 40 s. Data were normalized by dividing the quantity of target gene cDNA by the quantity of GAPDH cDNA to correct for variability in individual samples. Parallel reactions were run using RNA sample as template to assess the degree of contaminating genomic DNA. Negative control reactions without template were also performed.
Electric cell-substrate impedance sensing. Electric cell-substrate impedance sensing (ECIS) was used to assess in vitro endothelial barrier function by measuring transendothelial resistance (TER), as we have described previously (35) . Briefly, MLMVEC were grown to confluency on gold electrodes, treated with imatinib (1, 10, and 20 M) for 4 h, exposed to 250 or 500 M H 2O2, and TER was measured.
Isolated mouse lungs. The in situ isolated perfused mouse lung preparation was performed as previously described (17, 46) . Briefly, mice were anesthetized with intraperitoneal ketamine (150 mg/kg) and acetylpromazine (15 mg/kg) and a tracheostomy was performed. The mouse was ventilated at 6 ml/kg tidal volume at a rate of 120 breaths/min (MiniVent Mouse Ventilator 845; Harvard Apparatus) with 3 mmHg end-expiratory pressure. A sternotomy was performed and cannuli inserted into the pulmonary artery and left heart. Inspired gas was changed to 21% O2-5% CO2. Lung perfusion was then begun with warmed BMOC-3 supplemented with 3% BSA in an open circuit. Flow was increased to 2.5 ml/min, and the lungs were flushed for 5 min to remove blood before establishing recirculation. Left atrial pressure was maintained at 6 mmHg. Either imatinib (1 M) or diluent was added, and the lungs were perfused for 2 h. To mimic clinical ischemia-reperfusion injury, injury was then induced with ischemia-reperfusion/anoxia-reoxygenation as described previously (46) . Perfusion was stopped, and the lungs were ventilated for 10 min with 100% N2. Ventilation was then stopped, and the lungs were allowed to deflate. After an additional 50 min, ventilation was resumed with 21% O2-5% CO2 and reperfusion was initiated. Samples of perfusate were taken at 0, 15, 30, and 60 min of reperfusion and assayed for lactate dehydrogenase (LDH). Vascular and airway pressures were monitored and recorded (PowerLab 4/30 computer system; ADInstruments, Colorado Springs, CO).
LDH assay. LDH activity was measured in perfusate samples using the Promega CytoTox96 Non-Radioactivity Cytotoxicity Assay (Promega, Madison, WI) according to the manufacturer's instructions.
Statistics. All time-course measurements or other data incorporating two factors were analyzed using a two-factor ANOVA with either one-or two-repeated measures. Other data were analyzed using the appropriate Student's t-test for comparisons between two groups or a randomized one-factor ANOVA with least significant difference post hoc testing to compare mean values from multiple treatment groups.
Prism GraphPad software was used for statistical calculations. Nonnormal data were logarithmically converted before analysis. Values presented in text are means Ϯ SE. Differences were considered significant when P Յ 0.05.
RESULTS

Effect of PKG I activation on c-Abl activation and nuclear
translocation. c-Abl activity is regulated by phosphorylation of several tyrosine residues. Phosphorylation of tyrosine Y245 is necessary for c-Abl activation and is thus a marker of c-Abl activity (5, 21, 57) . To determine if PKG I activation inhibits c-Abl activity, we treated MLMVEC with the membranepermeant cGMP analog 8pCPT-cGMP (50 M) for 30 min before a 15-min exposure to H 2 O 2 . In untreated cells, exposure to H 2 O 2 resulted in a rapid (15 min) increase in active c-Abl, as measured by phosphorylation of Y245 (Fig. 1A) . In contrast, treatment with 8pCPT-cGMP for 30 min completely abrogated the increase in phospho-Y245 c-Abl ( Fig. 1A ; n ϭ 5; P Ͻ 0.05). Notably, 30 min of 8pCPT-cGMP treatment did not affect levels of total c-Abl protein. To confirm that activated PKG I inhibits c-Abl kinase activity, we assessed phosphorylation of p73, a member of the p53 family and established c-Abl substrate (33) . Upon exposure to cellular stress (e.g., DNA damage, oxidants, and ionizing radiation), p73 is phosphorylated on tyrosine 99 (Y99) by c-Abl, an activation event that subsequently leads to p73-mediated apoptosis (1, 60) . The phosphorylation of p73 Y99 is specific to c-Abl (13, 15, 31, 33) . MLMVEC were treated with 8pCPT-cGMP or diluent as described above and then exposed to H 2 O 2 for 15 min. In untreated MLMVEC, 500 M H 2 O 2 resulted in a marked increase in phospho-Y99 p73; this was prevented in 8pCPT-cGMP-treated cells ( Fig. 1B ; n ϭ 6; P Ͻ 0.05).
To demonstrate that the effect of 8pCPT-cGMP on c-Abl activity was due to PKG I activation, we utilized MLMVEC isolated from PKG I Ϫ/Ϫ mice (46) . As shown in Ϫ/Ϫ MLMVEC than in wild-type MLMVEC (Fig. 1D,  right) . H 2 O 2 was unable to increase c-Abl activity any further in PKG I Ϫ/Ϫ MLMVEC, and there was no inhibitory effect of 8pCPT-cGMP on H 2 O 2 -induced phosphorylation of Y245 (Fig. 1, C and D, left; n ϭ 4) .
To determine if an increase in endogenous endothelial cGMP would mimic the effect of 8pCPT-cGMP, we also examined the effect of ANP (10 nM) pretreatment on c-Abl activation. This concentration of ANP has been reported to by physiologic, and we and others have previously shown to increase intracellular cGMP (17, 46, 61) . As shown in Fig. 2 , in untreated MLMVEC, 250 and 500 M H2O2 caused a significant increase in phospho-Y245 c-Abl and phospho-Y99 P73 (n ϭ 7; P Ͻ 0.05). Treatment of MLMVEC with ANP for 30 min prevented Y245 c-Abl phosphorylation after a 15-min H 2 O 2 exposure ( Fig. 2A ; n ϭ 7; P Ͻ 0.05). ANP completely abrogated Y99 P73 phosphorylation after H 2 O 2 exposure; the absence of phospho-P73 bands precluded accurate densitometric quantification ( Fig. 2B; n ϭ 7) .
To further confirm the inhibitory effect of PKG I activation on c-Abl, we treated MLMVEC with 8pCPT-cGMP (50 M) or imatinib (20 M) for 30 min before exposure to 250 M H 2 O 2 . Fifteen minutes after H 2 O 2 exposure, cells were fixed for c-Abl and actin staining (nuclei visualized with DAPI; Fig. 3) . In untreated cells, c-Abl staining was localized in the cytoplasm and 8pCPT-cGMP treatment did not change c-Abl localization. However, exposure to H 2 O 2 resulted in nuclear localization of c-Abl as well as formation of actin stress fibers. Nuclear localization of c-Abl and actin stress fiber formation were prevented by treatment with 8pCPT-cGMP. Imatinib also prevented nuclear localization of c-Abl and actin stress fiber formation, mimicking the effects of PKG I activation (35) .
Effect of PKG I activation on c-Abl protein and mRNA expression. Treatment of MLMVEC with 8pCPT-cGMP for 30 min did not affect overall protein levels of c-Abl. We anticipated that the inhibitory effect of PKG I on c-Abl might result in a subsequent compensatory upregulation of total c-Abl protein (34, 58) . To assess this, we treated MLMVEC with 8pCPT-cGMP (50 M) for 4 h. Interestingly, this significantly decreased c-Abl protein by 29% (Ϯ8%) in wild-type MLMVEC (n ϭ 9; P Ͻ 0.01; Fig. 4A ). To determine whether this was due to decreased transcription of c-Abl mRNA, we preformed real-time quantitative PCR. There was no significant decrease in c-Abl mRNA after treatment with 8pCPT-cGMP (50 M, 4 h; n ϭ 7, data not shown), indicating that this is not a transcriptional effect. To confirm that the effect of 8pCPT-cGMP was due to PKG I activation, identical experiments were performed in PKG I Ϫ/Ϫ MLMVEC. In PKG Ϫ/Ϫ MLMVEC, there was no effect of 8pCPT-cGMP on c-Abl protein levels (Fig. 4B) . 
Effect of imatinib on antioxidant enzymes and oxidant scavenging in MLMVEC.
To determine whether inhibition of c-Abl would mimic the effects of PKG I activation, we utilized the c-Abl tyrosine kinase inhibitor imatinib. As shown in Fig. 5 , treatment of confluent MLMVEC monolayers with imatinib (10 and 20 M) for 4 h resulted in a dose-dependent increase in both catalase (Fig. 5A ) and GPx-1 (Fig. 5B) protein. Compared with diluent control, 10 M imatinib increased catalase and GPx-1 by 16% (Ϯ9%) and 24% (Ϯ13%), respectively (n ϭ 17, P Ͻ 0.05 for each). Twenty micromoles of imatinib increased catalase and GPx-1 by 37% (Ϯ11%) and 35% (Ϯ14%), respectively (n ϭ 4; P Ͻ 0.05 for both). To determine the mechanism underlying this increase, we performed quantitative RT-PCR for both catalase and GPx-1 mRNA after treatment with imatinib (20 M). Imatinib treatment did not significantly increase either catalase or GPx-1 mRNA in MLMVEC (n ϭ 3, data not shown). Because we hypothesized that the effect of PKG I activation on catalase and GPx-1 is mediated by PKG I -dependent inhibition of c-Abl, we wanted to determine if the effect of 8pCPT-cGMP on catalase and GPx-1 would be preserved in the presence of c-Abl inhibition. In imatinibtreated MLMVEC, there was no additional effect of 8pCPT-cGMP (50 M, 4 h) on either catalase or GPx-1 protein levels (P Ͼ 0.05; n ϭ 5-7, data not shown). Figure 6 shows the effect of imatinib treatment on the ability of MLMVEC to scavenge extracellular oxidants, as a surrogate of antioxidant enzyme activity These experiments were performed using an H 2 O 2 electrode to quantify the peak current (pA) generated after addition of a known concentration of H 2 O 2 to a measurement chamber containing diluent-or imatinib-treated MLMVEC (46) . Compared with diluenttreated MLMVEC, 20 M imatinib, but not 10 M imatinib, significantly decreased the peak measured H 2 O 2 concentration across a range of added concentrations (20, 50 , and 100 M H 2 O 2 ) by an average of 24 Ϯ 1% ( Fig. 6A ; n ϭ 9; P Ͻ 0.05 at all concentrations). To determine whether the effect of imatinib was downstream of PKG I , we performed an identical experiment in PKG I Ϫ/Ϫ MLMVEC. Compared with diluent control, imatinib (20 M) decreased the peak measured H 2 O 2 concentration by 11, 28, and 16% for added H 2 O 2 concentrations of 20, 50, and 100 M, respectively. These differences were significant for 50 and 100 M H 2 O 2 ( Fig. 6B ; n ϭ 5; P Ͻ 0.01). To confirm that this effect was due to specific inhibition of c-Abl by imatinib, we repeated these experiments using siRNA to knockdown c-Abl in MLMVEC. Compared with scramble control siRNA, c-Abl siRNA significantly decreased c-Abl by 43% (n ϭ 4; P Ͻ 0.01, data not shown) and significantly decreased the peak measured H 2 O 2 concentration by 21, 31, and 34% for added H 2 O 2 concentrations of 20, 50, and 100 M, respectively ( Fig. 6C ; n ϭ 6; P Ͻ 0.05).
Effect of imatinib on oxidant-induced pulmonary endothelial barrier dysfunction. Increases in antioxidant capacity would be expected to correlate with increased resistance to oxidant injury. To assess the effect of imatinib on oxidant-induced pulmonary endothelial barrier dysfunction, MLMVEC were allowed to grow to confluence on ECIS plates, placed in serum-free media, treated with diluent or imatinib (20 M) for 4 h, and then exposed to either 250 or 500 M H 2 O 2 . TER was used as a surrogate for barrier function: increased TER corresponds to decreased permeability, and decreased TER indicates increased permeability. There was no effect of imatinib on the baseline TER before H 2 O 2 exposure (data not shown). In diluent-treated cells, 250 M H 2 O 2 induced a small transient increase in TER, followed by a sustained decrease in TER. Imatinib pretreatment increased the initial increase in TER and significantly attenuated the subsequent decrease in TER ( Fig. 7A ; n ϭ 4; P Ͻ 0.05). After exposure to 500 M H 2 O 2 , diluenttreated MLMVEC monolayers demonstrated an immediate and sustained decrease in TER, which was significantly attenuated by imatinib pretreatment (Fig. 7B ; n ϭ 4; P Ͻ 0.05).
Effect of imatinib on H 2 O 2 -induced in vitro MLMVEC apoptosis and isolated lung perfusate LDH.
We assessed the effect of imatinib on H 2 O 2 -induced microvascular endothelial apoptosis as another index of oxidant injury. Increasing concentrations of H 2 O 2 significantly increased the percentage of condensed and fragmented nuclei by sixfold and eightfold compared with control for 100 M and 250 M H 2 O 2 , respectively (Fig. 8, A and B) . We next examined whether pretreatment with imatinib would protect against oxidant injury in the intact lung. Owing to differences in the protein concentration between cell media and perfusate (imatinib is highly protein bound), we utilized a lower concentration of imatinib (1 M) in these experiments. Isolated perfused mouse lungs were perfused with imatinib for 2 h before ischemia-reperfusion/hypoxia-reoxygenation injury was induced as previously described (46) . We monitored LDH release into the perfusate as an indication of endothelial cytotoxicity. As shown in Fig. 8C , in diluent-perfused lungs, ischemia-reperfusion/hypoxia-reoxygenation injury induced a rapid and sustained release of LDH into the perfusate from 15-60 min after reperfusion. Pretreatment with imatinib resulted in significant and near complete reduction in perfusate LDH from 15-60 min postreperfusion (n ϭ 3, P Ͻ 0.05).
DISCUSSION
This study presents two major findings. First, activation of PKG I inhibits c-Abl activity in pulmonary microvascular endothelial cells. Second, treatment with the c-Abl inhibitor imatinib mimics the effects of activated PKG I in MLMVEC, increasing the key antioxidant enzymes catalase and GPx-1, increasing scavenging of extracellular oxidants, ameliorating oxidant-induced lung endothelial barrier dysfunction, and decreasing oxidant-induced cell death in vitro and oxidantinduced endothelial cytotoxicity ex vivo. Importantly, in imatinib-treated MLMVEC, there was no additional effect of 8pCPT-cGMP on either catalase or GPx-1 protein levels.
An inhibitory effect of PKG I on c-Abl has not previously been reported. Our data show that 30 min of PKG I activation decreased c-Abl activity after H 2 O 2 exposure, as measured by phosphorylation of both c-Abl tyrosine 245 and p73 tyrosine 99. This occurred both after treatment with the cGMP analog 8pCPT-cGMP and after treatment with a physiologic dose of ANP, which has been previously shown to increase intracellular cGMP in MLMVEC (17, 46, 61) , demonstrating the physiologic relevance of PKG I -mediated c-Abl inhibition. c-Abl Y245 phosphorylation was unaffected by PKG I activation in PKG I Ϫ/Ϫ MLMVEC, confirming that this effect is PKG I dependent. We also found that baseline c-Abl Y245 phosphorylation is more than fourfold higher in PKG I Ϫ/Ϫ MLMVEC than in wild-type MLMVEC, further supporting an inhibitory effect of PKG I on c-Abl. PKG I activation also resulted in an abrogation of c-Abl nuclear translocation and actin stress fiber formation after H 2 O 2 exposure, an effect also seen after imatinib treatment. Because inhibition of c-Abl or the BCR-Abl fusion kinase has been associated with an increase in c-Abl protein, we were surprised to find that prolonged PKG I activation downregulated c-Abl protein expression in pulmonary microvascular endothelial cells. This finding was absent in PKG I Ϫ/Ϫ MLMVEC, confirming a negative regulatory role of PKG I on c-Abl expression.
We hypothesized that the antioxidant effects of PKG I activation are mediated by c-Abl inhibition. To begin to test this hypothesis, we reasoned that c-Abl inhibition should mimic the effect of PKG I activation on antioxidant regulation in pulmonary endothelium. To inhibit c-Abl, we used the c-Abl tyrosine kinase inhibitor imatinib. Similar to the effects of PKG I activation, imatinib increased the same key antioxidant enzymes catalase and GPx-1. Consistent with our hypothesis that PKG I increases catalase and GPx-1 by inhibiting c-Abl in the presence of imatinib, there was no additional effect of 8pCPT-cGMP on either catalase or GPx-1 protein levels. Both imatinib and c-Abl knockdown with siRNA enhanced scavenging of extracellular H 2 O 2 by MLMVEC. Moreover, imatinib ameliorated oxidant-induced lung endothelial barrier dysfunction, decreased oxidant-induced cell death in vitro, and prevented oxidant-induced endothelial cytotoxicity in isolated perfused mouse lungs. Taken together, these data suggest that the antioxidant effects of cGMP/PKG I signaling (16, 37, 43, 51) are mediated by inhibition of c-Abl. c-Abl inhibition with imatinib has previously been shown to attenuate oxidant-induced death (28, 44) . For example, imatinib treatment prevented lung fibrosis after radiation and bleomycin injury (32, 54) . The work of Cao et al. (8, 10) provided a possible mechanism for these effects, showing that c-Abl-mediated phosphorylation of the catalase tyrosine residues Y231 and Y386 targets catalase for ubiquitination and degradation. Inhibition of c-Abl would therefore be expected to increase catalase protein. Our current work is consistent with the observations of Cao et al. and, to our knowledge, is the first to demonstrate an increase in antioxidant proteins with imatinib treatment.
The mechanism by which PKG I , a serine-threonine kinase, could regulate c-Abl activity is unknown. c-Abl tyrosine kinase activity is tightly regulated by multiple mechanisms (12) . The resting state of c-Abl is an inactive conformation. Phosphorylation of the key tyrosine residues Y245, Y412, and Y89 results in kinase activation, and imatinib prevents Y412 phosphorylation (42) . In contrast, phosphorylation of Y272 promotes the inactive form and inhibits kinase activity. Whether PKG I directly phosphorylates a serine or threonine in c-Abl capable of regulating c-Abl activity or acts on c-Abl through an intermediary protein is currently unknown. An interesting candidate for this is a protein tyrosine phosphatase (PTP) that regulates c-Abl activity by dephosphorylating and deactivating c-Abl (12) . PKG I has been shown to increase the activity of PTPN12 (62) one of the PTPs known to inactivate c-Abl (6, 14, 24, 29, 36) .
We acknowledge that inhibition of c-Abl may have protective effects on endothelial function separate from the increased expression of antioxidant enzymes. For example, active c-Abl appears to contribute to actin cytoskeletal reorganization and stress fiber formation (20, 53) as well as phosphorylate caveolin-1, promoting transcellular pulmonary vascular permeability (23, 49) . In contrast, Dudek and colleagues (18, 55) have reported that c-Abl activation mediated the barrier enhancing effects of sphingosine-1 phosphate by phosphorylating myosin light chain kinase. The effect of c-Abl activation on pulmonary endothelial permeability is complex and may be stimulus dependent.
Finally, imatinib also inhibits several related tyrosine kinases: Abl-related gene (Arg) kinase, platelet derived growth factor receptor (PDGFR) kinase, and c-kit kinase (7) . Our data show that the effect of imatinib on oxidant scavenging (a reflection of antioxidant activity) is mimicked by c-Abl knockdown with siRNA, arguing for a c-Abl-specific effect of imatinib. Still, it is possible that inhibition of several or all of these kinases, in addition to or instead of c-Abl, is required to generate the antioxidant and barrier-protective effects of imatinib (25, 41) . In particular, inhibition of Arg by imatinib has recently been shown to enhance lung endothelial barrier function, an effect thought to be independent of c-Abl (3). It is also possible that PKG I exerts a "class effect" on Abl-family tyrosine kinases and inhibits other kinases besides c-Abl. For example, PKG I activation was shown to inhibit PDGFR in smooth muscle cells (4) .
In conclusion, we found that in MLMVEC, activation of PKG I led to a rapid inhibition of c-Abl tyrosine kinase activity and a slower posttranscriptional decrease in c-Abl expression. The c-Abl inhibitor imatinib mimicked the antioxidant and barrier-protective effects of PKG I activation in both wild-type and PKG I MLMVEC. Furthermore, in the presence of imatinib, there was no additional effect of PKG I activation on antioxidant protein quantity, suggesting that the PKG I -mediated effect was secondary to c-Abl inhibition. These results uncover a novel interaction between PKG I and c-Abl, provide a mechanism for the antioxidant effect of PKG I activation. Our data support the use of tyrosine kinase inhibitors as a novel pharmacological approach to the treatment of oxidant-induced ALI.
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